1. Home
  2. MESO vs TFIN Comparison

MESO vs TFIN Comparison

Compare MESO & TFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$16.47

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Triumph Financial Inc.

TFIN

Triumph Financial Inc.

HOLD

Current Price

$69.11

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MESO
TFIN
Founded
2004
1981
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.9B
IPO Year
2005
2014

Fundamental Metrics

Financial Performance
Metric
MESO
TFIN
Price
$16.47
$69.11
Analyst Decision
Strong Buy
Hold
Analyst Count
1
5
Target Price
N/A
$66.20
AVG Volume (30 Days)
180.2K
133.0K
Earning Date
02-26-2026
04-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
72.22
EPS
N/A
0.67
Revenue
N/A
N/A
Revenue This Year
$629.74
$7.27
Revenue Next Year
$30.65
$11.31
P/E Ratio
N/A
$103.88
Revenue Growth
N/A
N/A
52 Week Low
$13.05
$46.43
52 Week High
$21.50
$83.52

Technical Indicators

Market Signals
Indicator
MESO
TFIN
Relative Strength Index (RSI) 48.95 33.04
Support Level $15.37 $67.94
Resistance Level $17.10 $69.84
Average True Range (ATR) 0.44 1.87
MACD -0.09 -0.49
Stochastic Oscillator 1.06 10.61

Price Performance

Historical Comparison
MESO
TFIN

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

About TFIN Triumph Financial Inc.

Triumph Financial Inc is a financial holding company based in the United States. Along with its subsidiaries, the company operates in four reportable segments: Banking, Factoring, Payments, and Intelligence. The Banking segment, which generates maximum revenue, includes the operations of TBK Bank, offering traditional banking services. The Factoring segment provides working capital solutions to the trucking industry through the purchase of invoices generated by carriers at a discount. The Payments segment provides payment, audit, and other banking services for the over-the-road trucking industry, and the Intelligence segment operates to turn the over-the-road trucking data collected through the services offered into actionable insights for its customers.

Share on Social Networks: